BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24948692)

  • 1. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forodesine in the treatment of cutaneous T-cell lymphoma.
    Lewis DJ; Duvic M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycosis fungoides: pathophysiology and emerging therapies.
    Duvic M; Foss FM
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies.
    Ogura M; Tsukasaki K; Nagai H; Uchida T; Oyama T; Suzuki T; Taguchi J; Maruyama D; Hotta T; Tobinai K
    Cancer Sci; 2012 Jul; 103(7):1290-5. PubMed ID: 22448814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
    Galmarini CM
    IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
    Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
    Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
    Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
    Maruyama D; Tsukasaki K; Uchida T; Maeda Y; Shibayama H; Nagai H; Kurosawa M; Suehiro Y; Hatake K; Ando K; Yoshida I; Hidaka M; Murayama T; Okitsu Y; Tsukamoto N; Taniwaki M; Suzumiya J; Tamura K; Yamauchi T; Ueda R; Tobinai K
    Ann Hematol; 2019 Jan; 98(1):131-142. PubMed ID: 29974231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
    Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
    Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
    Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
    Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
    Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
    Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
    Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
    Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
    Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.